Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Psychedelic mushrooms, containing the active ingredient psilocybin, have shown remarkable potential in treating various ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

The government is preparing to fund the use of MDMA and psylocibin, otherwise known as ecstasy and magic mushrooms, as a ...